ES2215680T3 - Unidad unica de administracin que contiene una combinacion de tramadol y diclofenaco. - Google Patents
Unidad unica de administracin que contiene una combinacion de tramadol y diclofenaco.Info
- Publication number
- ES2215680T3 ES2215680T3 ES00942052T ES00942052T ES2215680T3 ES 2215680 T3 ES2215680 T3 ES 2215680T3 ES 00942052 T ES00942052 T ES 00942052T ES 00942052 T ES00942052 T ES 00942052T ES 2215680 T3 ES2215680 T3 ES 2215680T3
- Authority
- ES
- Spain
- Prior art keywords
- tramadol
- oral administration
- administration unit
- unit according
- diclofenac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims abstract description 74
- 229960004380 tramadol Drugs 0.000 title claims abstract description 73
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title claims abstract description 68
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 title claims abstract description 39
- 229960001259 diclofenac Drugs 0.000 claims abstract description 37
- 239000013543 active substance Substances 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000008188 pellet Substances 0.000 claims description 39
- 238000000576 coating method Methods 0.000 claims description 30
- 239000004480 active ingredient Substances 0.000 claims description 20
- 239000011248 coating agent Substances 0.000 claims description 19
- 230000003111 delayed effect Effects 0.000 claims description 19
- 239000011159 matrix material Substances 0.000 claims description 11
- 230000000979 retarding effect Effects 0.000 claims description 10
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 10
- 229960001193 diclofenac sodium Drugs 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 7
- 210000004051 gastric juice Anatomy 0.000 claims description 7
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims description 6
- 238000001125 extrusion Methods 0.000 claims description 6
- 238000005563 spheronization Methods 0.000 claims description 6
- 229960003107 tramadol hydrochloride Drugs 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920001268 Cholestyramine Polymers 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229960001860 salicylate Drugs 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- 229920013820 alkyl cellulose Polymers 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 229960004515 diclofenac potassium Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- -1 tramadol salts hydrochloride Chemical class 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 229920000178 Acrylic resin Polymers 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000479842 Pella Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- LUCXOFIZQAAKNM-UHFFFAOYSA-L calcium;2-[2-(2,6-dichloroanilino)phenyl]acetate Chemical compound [Ca+2].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl.[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl LUCXOFIZQAAKNM-UHFFFAOYSA-L 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000012461 cellulose resin Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940121367 non-opioid analgesics Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000011970 polystyrene sulfonate Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19927689A DE19927689A1 (de) | 1999-06-17 | 1999-06-17 | Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
| DE19927689 | 1999-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2215680T3 true ES2215680T3 (es) | 2004-10-16 |
Family
ID=7911586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00942052T Expired - Lifetime ES2215680T3 (es) | 1999-06-17 | 2000-06-13 | Unidad unica de administracin que contiene una combinacion de tramadol y diclofenaco. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20020156133A1 (enExample) |
| EP (1) | EP1185253B1 (enExample) |
| JP (1) | JP4889897B2 (enExample) |
| AT (1) | ATE260650T1 (enExample) |
| AU (1) | AU778151B2 (enExample) |
| CA (1) | CA2377174C (enExample) |
| DE (2) | DE19927689A1 (enExample) |
| DK (1) | DK1185253T3 (enExample) |
| ES (1) | ES2215680T3 (enExample) |
| HK (1) | HK1045113A1 (enExample) |
| HU (1) | HUP0201687A3 (enExample) |
| MX (1) | MXPA01013046A (enExample) |
| NZ (1) | NZ516593A (enExample) |
| PT (1) | PT1185253E (enExample) |
| WO (1) | WO2000078294A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10108122A1 (de) | 2001-02-21 | 2002-10-02 | Gruenenthal Gmbh | Arzneimittel auf Basis von Tramadol |
| US20030134810A1 (en) * | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
| EP1364649A1 (en) * | 2002-05-23 | 2003-11-26 | Cilag AG | Adduct of topiramate and tramadol hydrochioride and uses thereof |
| EP1628685B1 (en) | 2003-04-25 | 2010-12-08 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| US20050265955A1 (en) * | 2004-05-28 | 2005-12-01 | Mallinckrodt Inc. | Sustained release preparations |
| WO2006110157A2 (en) | 2004-07-27 | 2006-10-19 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates as anti hiv agents |
| CN101257894A (zh) | 2005-07-07 | 2008-09-03 | 法纳姆公司 | 高水溶性药物的缓释药物组合物 |
| US20070009591A1 (en) * | 2005-07-07 | 2007-01-11 | Trivedi Jay S | ACE inhibitor formulation |
| EP1785412A1 (en) * | 2005-11-14 | 2007-05-16 | IPCA Laboratories Limited | Tramadol recovery process |
| DE102006006532B4 (de) * | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
| DK2018160T3 (da) | 2006-03-16 | 2012-02-06 | Tris Pharma Inc | Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser |
| JP2008208078A (ja) * | 2007-02-27 | 2008-09-11 | Takada Seiyaku Kk | 分割錠剤 |
| HRP20120700T1 (hr) | 2008-07-08 | 2012-09-30 | Gilead Sciences | SOLI SPOJEVA INHIBITORA HIV-a |
| DE102008056312A1 (de) | 2008-11-07 | 2010-05-12 | Biogenerics Pharma Gmbh | Verwendung von Mikrotabletten als Lebens-und Futtermittelzusatz |
| KR20130129070A (ko) * | 2010-07-12 | 2013-11-27 | 융신 파마슈티칼 인더스트리얼 컴파니 리미티드 | 트라마돌의 디클로페낙 염 |
| US8623409B1 (en) | 2010-10-20 | 2014-01-07 | Tris Pharma Inc. | Clonidine formulation |
| US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| ES2892402T3 (es) | 2017-08-01 | 2022-02-04 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| CN110755396B (zh) * | 2019-12-06 | 2022-04-08 | 北京悦康科创医药科技股份有限公司 | 一种布洛芬缓释小丸及其制备方法 |
| US11918689B1 (en) | 2020-07-28 | 2024-03-05 | Tris Pharma Inc | Liquid clonidine extended release composition |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8521350D0 (en) * | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
| DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| AU661723B2 (en) * | 1991-10-30 | 1995-08-03 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
| US5919826A (en) * | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
| DE19732928C2 (de) * | 1997-07-31 | 2000-05-18 | Gruenenthal Gmbh | Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel |
-
1999
- 1999-06-17 DE DE19927689A patent/DE19927689A1/de not_active Ceased
-
2000
- 2000-06-13 PT PT00942052T patent/PT1185253E/pt unknown
- 2000-06-13 ES ES00942052T patent/ES2215680T3/es not_active Expired - Lifetime
- 2000-06-13 WO PCT/EP2000/005386 patent/WO2000078294A2/de not_active Ceased
- 2000-06-13 MX MXPA01013046A patent/MXPA01013046A/es active IP Right Grant
- 2000-06-13 JP JP2001504359A patent/JP4889897B2/ja not_active Expired - Fee Related
- 2000-06-13 DK DK00942052T patent/DK1185253T3/da active
- 2000-06-13 CA CA002377174A patent/CA2377174C/en not_active Expired - Fee Related
- 2000-06-13 AT AT00942052T patent/ATE260650T1/de active
- 2000-06-13 NZ NZ516593A patent/NZ516593A/en not_active IP Right Cessation
- 2000-06-13 DE DE50005529T patent/DE50005529D1/de not_active Expired - Lifetime
- 2000-06-13 EP EP00942052A patent/EP1185253B1/de not_active Expired - Lifetime
- 2000-06-13 AU AU56805/00A patent/AU778151B2/en not_active Ceased
- 2000-06-13 HU HU0201687A patent/HUP0201687A3/hu unknown
- 2000-06-13 HK HK02106641.8A patent/HK1045113A1/zh unknown
-
2001
- 2001-12-17 US US10/016,130 patent/US20020156133A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ516593A (en) | 2003-08-29 |
| ATE260650T1 (de) | 2004-03-15 |
| CA2377174C (en) | 2009-07-28 |
| EP1185253B1 (de) | 2004-03-03 |
| DE19927689A1 (de) | 2000-12-21 |
| DE50005529D1 (de) | 2004-04-08 |
| WO2000078294A2 (de) | 2000-12-28 |
| WO2000078294A3 (de) | 2001-03-29 |
| AU778151B2 (en) | 2004-11-18 |
| MXPA01013046A (es) | 2002-06-04 |
| CA2377174A1 (en) | 2000-12-28 |
| PT1185253E (pt) | 2004-07-30 |
| DK1185253T3 (da) | 2004-04-05 |
| JP2003502360A (ja) | 2003-01-21 |
| US20020156133A1 (en) | 2002-10-24 |
| HUP0201687A2 (en) | 2002-09-28 |
| JP4889897B2 (ja) | 2012-03-07 |
| HK1045113A1 (zh) | 2002-11-15 |
| HUP0201687A3 (en) | 2005-07-28 |
| AU5680500A (en) | 2001-01-09 |
| EP1185253A2 (de) | 2002-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2215680T3 (es) | Unidad unica de administracin que contiene una combinacion de tramadol y diclofenaco. | |
| ES2226886T3 (es) | Forma de administracion de accion retardada que contiene sacarinato de tramadol. | |
| CA2348090C (en) | Oral pulsed dose drug delivery system | |
| JP5845172B2 (ja) | 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物 | |
| ES2231221T3 (es) | Tableta multicapa para la administracion de una combinacion fija de tramadol y de diclofenac. | |
| ES2247320T3 (es) | Medicamento a base de tramadol. | |
| JP6068142B2 (ja) | 浮遊微粒剤 | |
| ES2260042T3 (es) | Formas farmaceuticas de administracion oral que contienen tramadol de liberacion retardada. | |
| ES2170136T5 (es) | Formulaciones opioides para el tratamiento del dolor. | |
| ES2529570T3 (es) | Formulaciones multiparticuladas de pantoprazol | |
| ES2778864T3 (es) | Formulación compuesta, que comprende un comprimido esferoidal de múltiples unidades (MUST) encapsulado en una cápsula dura y un método para preparar el mismo | |
| ES2197369T3 (es) | Composiciones farmaceuticas para la liberacion sostenida de fluvastatina inhibidora de hmg-coa reductasa. | |
| EA023305B1 (ru) | Гранулят гамма-гидроксимасляной кислоты | |
| CN101669914A (zh) | 产生至少一个定时脉冲的控释药物剂型 | |
| ES2482771T3 (es) | Composiciones y métodos para inhibir la secreción de ácido gástrico | |
| WO2004066924A2 (en) | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid | |
| CN103889455A (zh) | 稳定化乙哌立松医药组成物及含有上述组成物的缓释制剂 | |
| ES2303314T3 (es) | Formulaciones de liberacion prolongada de dipiridamol y procedimiento para su preparacion. | |
| JP2010524926A (ja) | ウルソデオキシコール酸の高用量組成物 | |
| WO2015142178A1 (en) | Bile acid composition with enhanced solubility | |
| EP2277511B1 (en) | Extended release pharmaceutical compositions of levetiracetam | |
| US8173164B2 (en) | Oral administration forms for administering a fixed tramadol and diclofenac combination | |
| RU2820820C2 (ru) | Фармацевтические композиции акотиамида и ингибитора протонной помпы | |
| WO2006124898A1 (en) | Morphine sulfate formulations | |
| AU2004200325B2 (en) | Oral Pulsed Dose Drug Delivery System |